Head to Head Review: Crescent Biopharma (NASDAQ:CBIO) and XTL Biopharmaceuticals (NASDAQ:XTLB)

Crescent Biopharma (NASDAQ:CBIO) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Valuation and Earnings

This table compares Crescent Biopharma and XTL Biopharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84 million	48.79	-$153.94 million	($6.72)	-2.12
XTL Biopharmaceuticals	$450,000.00	12.69	-$6.97 million	($0.64)	-3.77

XTL Biopharmaceuticals has lower revenue, but higher earnings than Crescent Biopharma. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Crescent Biopharma and XTL Biopharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1	1	2	2	2.83
XTL Biopharmaceuticals	1	0	0	0	1.00

Crescent Biopharma presently has a consensus target price of $29.60, suggesting a potential upside of 107.87%. Given Crescent Biopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Crescent Biopharma is more favorable than XTL Biopharmaceuticals.

Profitability

This table compares Crescent Biopharma and XTL Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
XTL Biopharmaceuticals	N/A	N/A	N/A

Institutional & Insider Ownership

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Crescent Biopharma has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Summary

Crescent Biopharma beats XTL Biopharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Crescent Biopharma

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.